The penetration of generic and the end of patent’s protection for major blockbusters (65 billion off patent by 2012)* urges cost reduction & strengthening of the pipeline. The pressure on costs will induce the implementation of a new organizational model characterized by more analytical and value adding activities and a higher level of shared processes.
The frequency & diversity of governmental interventions increases difficulty to predict future earnings and require increased strategic flexibility.
The import/export patterns and the counterfeiting urges the review of the traditional supply chain model.
In order to face these industry challenges, most companies will need to answer the following key questions:
Deloitte has helped several big Life Sciences companies in:
*82 billion in sales is at risk through 2014 (source: datamonitor)